SCHEMBL6648871

SCHEMBL6648871

Cc1ccc(C(=O)Nc2ccc3c(c2)CCN(Cc2ncn(C(c4ccccc4)(c4ccccc4)c4ccccc4)n2)C3)c(N2CCC(C)CC2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN10A Q9Y5Y9 3/20 0.37
▸ SMN1; SMN2 Q16637 4/20 0.36
▸ MAPT P10636 2/20 0.36
▸ PLAU P00749 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ KDM4E B2RXH2 3/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ TRPV1 Q8NER1 1/20 0.35
▸ LMNA P02545 2/20 0.34
▸ NOD1 Q9Y239 2/20 0.34
▸ KDR P35968 2/20 0.34
▸ KIF18A Q8NI77 1/20 0.34
▸ ITGB3 P05106 1/20 0.34
▸ ITGA2B P08514 1/20 0.34
▸ GAA P10253 1/20 0.33
▸ PIN1 Q13526 1/20 0.33
▸ TMPRSS2 O15393 1/20 0.33
▸ SYK P43405 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6645706 0.86 NOD1 (0.38) SMN1; SMN2PLAUKDM4EALDH1A1MEN1
SCHEMBL6644942 0.82 PLAU (0.40) SCN10ASMN1; SMN2MAPTPLAUTP53
SCHEMBL6643995 0.81 NOD1 (0.41) SMN1; SMN2PLAUKDM4EMEN1KMT2A
SCHEMBL6645494 0.80 NOD1 (0.39) SMN1; SMN2MAPTPLAUKDM4EALDH1A1
SCHEMBL6644846 0.77 PRKAA2 (0.48) SCN10ASMN1; SMN2PLAUKDM4EALDH1A1
SCHEMBL6490283 0.73 NOD1 (0.39) SMN1; SMN2KDM4EMEN1KMT2ALMNA
SCHEMBL6643916 0.73 NPC1 (0.44) SCN10ASMN1; SMN2MAPTTP53KDM4E
SCHEMBL6645902 0.72 ESR2 (0.48) SCN10AKDM4EALDH1A1LMNATMPRSS2
SCHEMBL6645188 0.71 SCN10A (0.42) SCN10ASMN1; SMN2MAPTTP53ALDH1A1
SCHEMBL6646048 0.71 EGFR (0.45) SCN10ASMN1; SMN2MAPTTP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR SCN10A 1201/4885SMN1; SMN2 1836/4885MAPT 4101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback